

UNIVERSITY HEALTH CENTER

University of Georgia Athens, GA 30602-1755 Phone: 706-542-1162 Fax Nr: 706-542-4959

or 706-583-0777

NAME:	
UGA ID#:	
Date of Birth:	
Phone Number:	

CERTIFICATE OF IMMUNIZATION (REQUIRED TO REGISTER FOR CLASS)

(Ok to attach GRITS or other certified immunization record)

REQUIRED IMMUNIZATIONS	REQUIREMENT (MM/DD/YYYY)	REQUIRED FOR:
MMR	#1 / /	All foreign-born students regardless of year born US/Consider students born in 1057 or leter.
(Measles, Mumps, Rubella)		US/Canadian students born in 1957 or later
	#2/	• 1 st due at 12 months of age or older
OR	OR	2 nd dose administered no earlier than 28 days after 1 st dose
	J.,	dose
Measles (Rubeola)	#1/#2/	US/Canadian students born in 1957 or later
AND	OR Attached antibody titer (blood test) lab report	If antibody titer does not indicate immunity, injection
Mumps	#1/#2	series required.
Rubella (German Measles)	#1 / /	1 st due at 12 months of age or older
Rubella (German Weastes)	OR Attached antibody titer (blood test) lab report	2 nd dose administered no earlier than 28 days after 1 st
		dose • SELF/PARENTAL REPORTED HISTORY OF DISEASE
	#1/#2/	NOT ACCEPTED
	OR	All foreign-born students regardless of year born.
	Attached antibody titer (blood test) lab report	US/Canadian born students born during or after 1980.
Varicella (Chicken Pox)	OR	1 st due at 12 months of age or older
	Definitive diagnosis of varicella by healthcare	2 nd dose administered no earlier than 28 days after 1 st
	provider. Provide statement from provider	dose
	verifying previous infection.	If antibody titer does not indicate immunity, injection
Tetanus, Diphtheria, Pertussis	Tdap / / (REQUIRED)	One dose of Tdap for <i>all</i> students within past 10 years.
(Tdap)	If unable at home country, obtain at UGA	
	#1 / /	All Students who will be 18 or younger on the first day of
Hepatitis B	#2 / /	class. • If antibody titer does not indicate immunity, injection
	#3 / /	series required.
		You <u>must</u> submit the antibody titer report on lab letterhead
	OR Attached antibody titer (blood test) lab	from a certified lab with definitive lab values in English.
Tuberculosis (TB)	All students MUST complete the Tuberculosis Screening Questionnaire found on	If the answer to any of the TB screening questions is YES, then must complete the TB Clinical Risk Assessment Part II of
· use · uses (· s)	healthcenter.uga.edu/info/forms	Form, including TST or IGRA by physician.
	, ,	All newly admitted UGA students living in Campus Housing,
Meningococcal Vaccine	#1/	or
ACWY(MCV4)	#2/	Sorority or Fraternity Houses.
(Strongly Recommended for all students <22)	□ Menactra □ Menyeo	NOTE: A student may sign a statement of understanding in lieu of providing proof of immunization.
(Strongly Recommended for all students \22)	a Menaetra a Menveo	Review meningitis disease information at:
		healthcenter.uga.edu/healthtopics/meningitis
Recommended Vaccines:		
Meningitis B Vaccine: #1_//_	#2/ #3/	🗖 Bexsero 📮 Trumenba
Hepatitis A: #1/_/#2/	/HPV: #1/#2/#3	
Influenza://COVID: #1_		🗖 Pfizer 🗖 Moderna 🗖 J&J
	I affirm that the immunizations required by	Request for Permanent Medical Contraindication
, , , , , , , , , , , , , , , , , , , ,	are in conflict with my religious beliefs	(Attach Verification by HealthCare Provider)
I understand I am subject to exclu	sion in the event of an outbreak of	
disease which immunization is req	uired. (Attach Notarized Affidavit)	
REQUIRED SIGNATURE OF PHYSICIAN C	DR HEALTH FACILITY:	
NameAo	ddressPho	ne Number
Signature	Date	e
Jignature	Date	<u> </u>
Revised: 6/17; 5/19; 11/2021		



Form Reviewed: 3/17; 3/18; 7/21 Form Revised: 3/2/2016; 5/22

UNIVERSITY HEALTH CENTER

University of Georgia Athens, GA 30602-1755 Phone: 706-542-1162 Fax Nr: 706-542-4959

or 706-583-0777

NAME:	
UGA ID#:	
Date of Birth: _	

Part I: Tuberculosis (TB) Screening Questionnaire

Please answer the following	ng questions:				
1. Have you ever had close contact with persons known or suspected to have active TB disease?					
2. Were you born in one of (If YES, please CHECK the coun	the countries listed below that try, below)	have a high incidence of	factive TB disease?	□Yes □ No)
□ Afghanistan □ Algeria □ Angola □ Anguilla □ Argentina □ Arrenia □ Azerbaijan □ Bangladesh □ Belarus □ Belize □ Benin □ Bhutan □ Bolivia (Plurinational Stateof) □ Bosnia and Herzegovina □ Botswana □ Brazil □ Brunei Darussalam □ Bulgaria □ Burkina Faso □ Burundi □ Cabo Verde □ Cambodia □ Cameroon □ Central African Republic □ Chad □ China □ China, Hong Kong SAR □ China, Macao SAR □ Colombia	□Comoros □Congo □Côte d'Ivoire □Dem People's Republic of Korea □Dem Rep of the Congo □Djibouti □Dominica □Dominican Republic □Ecuador □El Salvador □Equatorial Guinea □Eritrea □Eswatini □Ethiopia □Fiji □French Polysnesia □Gabon □Gambia □Georgia □Ghana □Greenland □Guatemala □Guam □Guinea □Guinea □Guinea □Guinea □Guinea □Guinea □Guinea □Guyana □Haiti □Honduras □India □Indonesia	□ Iraq □ Kazakhstan □ Kenya □ Kiribati □ Kuwait □ Kyrgyzstan □ Lao People's Dem Rep □ Latvia □ Lesotho □ Liberia □ Libya □ Lithuania □ Madagascar □ Malawi □ Malaysia □ Maldives □ Mali □ Matta □ Marshall Islands □ Mauritania □ Mexico □ Micronesia □ Mongolia □ Morocco □ Mozambique □ Myanmar □ Namibia □ Nauru □ Nepal □ Nicaragua □ Niger	□Nigeria □Niue □Northern Marina Islands □Pakistan □Palau □Panama □Papua New Guinea □Paraguay □Peru □Philippines □Qatar □Republic of Korea □Republic of Moldova □Romania □Russian Federation □Rwanda □Sao Tome and Principe □Senegal □Sierra Leone □Singapore □Solomon Islands □South Sudan □Sri Lanka □South Sudan □Sri Lanka □Sudan □Sri Lanka □Sudan □Sri Lanka □Suriname □Tajikistan □Thailand □Timor-Leste □Togo □Yokelau □Turkmenistan	□Tuvalu □Uganda □Ukraine □Un. Rep. o □Uruguay □Uzbekistan □Vanuatu □Venezuela □Viet Nam □Yemen □Zambia □Zimbabwe	ı (Bol. Rep.)
	ation Global Health Observatory, Tub	erculosis Incidence 2012. Cou	untries with incidence rates of≥	20 cases per 100),000
3. Have you had frequent (≥to	refer to http://apps.who.int/ghodata. wice/year) or prolonged (> 1 montlevalence of TB disease? (If yes, Cl			☐ Yes	□ No
**If YES to questions 2 an (month and year) **	d/or 3: Date last traveled to high	risk country			
• ,	nd/or employee of high-risk congr	egate settings (e.g., correct	ional	☐ Yes	☐ No
facilities, long-term care fa	☐ Yes	☐ No			
5. Have you been a volunteer TB disease?	or health-care worker who served	clients who are at increase	d risk for active		
6. Have you ever been a men	mber of any of the following gro ctive TB disease – medically und			M. □ Yes	□ No
	the above questions, University Hea e questions is NO, no further testing		eceive TB testing (complete Pa	urt II).	
Signature of Student		Date: _			
(Or Signature of Parent if stud	dent is < 18 yrs. old)	_			



tested.

UNIVERSITY HEALTH CENTER

University of Georgia Athens, GA 30602-1755 Phone: 706-542-1162 Fax Nr: 706-542-4959

or 706-583-0777

NAME:	
UGA ID#:	
CG/11D#	
Date of Birth:	

PART II. CLINICAL ASSESSMENT BY HEALTHCARE PROVIDER

Clinicians should review and verify the information in Part I. Persons answering YES to any are candidates for either Mantoux tuberculin skin test (TST) or Interferon Gamma Release previous positive test has been documented.			
History of a positive TB skin test or IGRA blood test? (If yes, document below)		Yes	☐ No
History of BCG vaccination? (If yes, consider IGRA if possible.)		Yes	☐ No
1. TB Symptom Check ¹ Does the student have signs or symptoms of active pulmonary tuberculosis disease? *If NO, proceed to 2 and 3. If YES, check below:		Yes	□ No
 □ Cough (especially if lasting for 3 weeks or longer) with or without sputum production □ Coughing up blood (hemoptysis) □ Chest pain □ Loss of appetite □ Unexplained weight loss □ Night sweats □ Fever 	n		
Proceed with additional evaluation to exclude active tuberculosis disease including tuberculary (PA and lateral), and sputum evaluation as indicated.	ulin s	skin testing,	chest
2. Tuberculin Skin Test(TST) (TST result should be recorded as actual millimeters (mm) of induration, transverse diam write "0". The TST interpretation should be based on mm of induration as well as risk factors.			ation,
Date Given:/			
Result:mm of induration **Interpretation: positivenegative			
Date Given:/ Date Read://			
Result:mm of induration **Interpretation: positivenegative			
**Interpretation guidelines			
≥5 mm is positive: □ Recent close contacts of an individual with infectious TB □ Persons with fibrotic changes on a prior chest x-ray, consistent with past TB disease □ Organ transplant recipients and other immunosuppressed persons (including receiving equivalent of >15 □ HIV-infected persons	5 mg/c	l of prednison	e for >1 month.
≥10 mm is positive: □ Recent arrivals to the U.S. (<5 years) from high prevalence areas or who resided in one for a significant in Injection drug users □ Mycobacteriology laboratory personnel □ Residents, employees, or volunteers in high-risk congregate settings	*amoi	unt of time	
☐ Persons with medical conditions that increase the risk of progression to TB disease including silicosis failure, certain types of cancer (leukemias and lymphomas, cancers of the head, neck, or lung), gastr weight loss of at least 10% below ideal body weight.			
≥15 mm is positive: □ Persons with no known risk factors for TB who, except for certain testing programs required by law or re	saulat	ion would oth	namuriga nat ha



UNIVERSITY HEALTH CENTER

University of Georgia Athens, GA 30602-1755 Phone: 706-542-1162

Fax Nr: 706-542-4959 or 706-583-0777

NAME:	
UGA ID#:	
Date of Birth:	

Recently infected with <i>M. tuberculosis</i> History of untreated or inadequately tre			sons with f	ibrotic changes on chest radiograph	
consistent with prior TB disease Receiving immunosuppressive therapy				, .	S
equivalent to/greater than 15 mg of pre- transplantation					
 Diagnosed with silicosis, diabetes mell Have had a gastrectomy or jejunoileal 		failure, leuke	emia, or ca	ncer of the head, neck, or lung	
☐ Weigh less than 90% of their ideal bod	y weight				
☐ Cigarette smokers and persons who abu	•				
••Populations defined locally as having an increased populations	incidence of disease d	ue to <i>M. tuberci</i>	<i>ılosis</i> , includ	ing medically underserved, low-income	
Student agrees to receive treatment					
Student declines treatment at this ti					
Student declines treatment at this ti	me				
Required Signature of Healthcare Provider:					
Name:		Phone:			_
Address:		City, State,	Zip Code:		_

Form Created: Form Reviewed: 3/17; 3/18; 7/21 Form Revised: 3/2/2016; 5/22